Vmbook Online ordering
Pdl Biopharma Inc
PDL BioPharma, Inc. (PDLI) is a biotechnology company with a focus on acquiring and developing clinically critical, high-potential therapeutic assets at key development and commercialization stages. The company's primary asset is its subsidiary, Noden Pharma DAC, which markets a suite of products for the treatment of cardiovascular diseases and disorders.
The company had a revenue of $118.38 million in the fiscal year 2020, representing a decrease of 18.9% as compared to the revenue of $145.74 million in the fiscal year 2019. However, it's important to note that the financial performance of PDL BioPharma in recent years has been inconsistent. The company's net loss for the fiscal year 2020 was $21.55 million, compared to a net income of $26.91 million in the fiscal year 2019.
In terms of growth, PDL BioPharma has been making significant efforts to expand its product portfolio and geographic reach through strategic collaborations and licensing agreements. In recent years, the company has entered into several agreements with biotechnology and pharmaceutical companies to develop and commercialize its therapeutic assets.
For instance, in 2020, PDL BioPharma entered into an exclusive licensing agreement with Daewoong Pharmaceutical Co., Ltd for the development and commercialization of PDL's exenatide extended-release (ER) product for the treatment of type 2 diabetes in several countries in Asia and South America.
In summary, PDL BioPharma is a biotechnology company with a focus on acquiring and developing clinically critical, high-potential therapeutic assets at key development and commercialization stages, with its primary asset being its subsidiary Noden Pharma DAC. Despite experiencing a decline in revenue and net income in recent years, the company has made significant efforts to expand its product portfolio and geographic reach through strategic collaborations and licensing agreements.
It's worth noting that investing in biotechnology companies, particularly those that are not yet profitable, can be risky and that investors should conduct their own due diligence prior to making investment decisions.